{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T03:10:17Z","timestamp":1792465817618,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T00:00:00Z","timestamp":1655596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.leukres.2022.106885","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T11:33:28Z","timestamp":1654688008000},"page":"106885","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center"],"prefix":"10.1016","volume":"119","author":[{"given":"Tamer","family":"Othman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Moskoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendolyn","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Tenold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Azenkot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"Krackeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha C.","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Kaesberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanna L.","family":"Welborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Wun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseem S.","family":"Esteghamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasmus T.","family":"Hoeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehrdad","family":"Abedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2022.106885_bib1","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/1097-0142(19951215)76:12<2393::AID-CNCR2820761203>3.0.CO;2-P","article-title":"Acute lymphoblastic leukemia a comprehensive review with emphasis on biology and therapy","volume":"76","author":"Cortes","year":"1995","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2022.106885_bib2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","article-title":"Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"18","author":"Kantarjian","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2022.106885_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2022.106885_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: a comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"issue":"12","key":"10.1016\/j.leukres.2022.106885_bib5","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","article-title":"Treatment of Philadelphia chromosome\u2013positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate","volume":"103","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2022.106885_bib6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-021-00860-1","article-title":"Indications for allogeneic HCT in adults with acute lymphoblastic leukemia in first complete remission","volume":"22","author":"Arslan","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"issue":"15","key":"10.1016\/j.leukres.2022.106885_bib7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S1470-2045(15)00207-7","article-title":"Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study","volume":"16","author":"Jabbour","year":"2015","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2022.106885_bib8","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2022.106885_bib9","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1182\/blood-2009-12-261586","article-title":"First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia","volume":"116","author":"Ravandi","year":"2010","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.leukres.2022.106885_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/blood-2019-125146","article-title":"Long-term safety and efficacy of Hyper-CVAD plus ponatinib as frontline therapy for adults with philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"134","author":"Short","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106885_bib11","unstructured":"\u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf\u3009. Accessed September 5."},{"issue":"24","key":"10.1016\/j.leukres.2022.106885_bib12","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy With a modified Hyper-CVAD and rituximab regimen improves outcome in de novo philadelphia chromosome\u2013negative precursor B-Lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2022.106885_bib13","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3324\/haematol.2019.220756","volume":"105","author":"Lazaryan","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.leukres.2022.106885_bib14","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1200\/JCO.2016.69.0073","article-title":"High frequency and poor outcome of philadelphia chromosome-like acute lymphoblastic leukemia in adults","volume":"35","author":"Roberts","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.leukres.2022.106885_bib15","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/blood-2009-09-245944","article-title":"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic\/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia","volume":"115","author":"Harvey","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2022.106885_bib16","unstructured":"Apostolidou E., Lachowiez C., Juneja HS, Qiao W., Ononogbu O., Miller-Chism CN, et al. Clinical Outcomes of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia in a County Hospital System. Clinical Lymphoma, Myeloma and Leukemia."},{"issue":"3","key":"10.1016\/j.leukres.2022.106885_bib17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clml.2016.11.002","article-title":"Hyper-CVAD compared With BFM-like chemotherapy for the treatment of adult acute lymphoblastic leukemia. A retrospective single-center analysis","volume":"17","author":"El-Cheikh","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2022.106885_bib18","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1016\/S2152-2650(20)30698-4","article-title":"ALL-394: Hyper-CVAD vs. BFM-Like regimens in adult patients with philadelphia-negative acute lymphoblastic leukemia: a single-center experience","volume":"20","author":"Lasheen","year":"2020","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"key":"10.1016\/j.leukres.2022.106885_bib19","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S2152-2650(21)01663-3","article-title":"ALL-318: real-world outcomes of adults with philadelphia chromosome-positive acute lymphoblastic leukemia who did not receive allogeneic stem cell transplant at the University of Michigan","volume":"21","author":"Foucar","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2022.106885_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2017.06.010","article-title":"The Dana Farber consortium protocol (DFCP) vs. classic Hyper-CVAD for treatment of acute lymphoblastic leukemia in patients <50 Y. Single institution experience","volume":"60","author":"Alabdulwahab","year":"2017","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.leukres.2022.106885_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000375258","article-title":"Is the BFM Regimen Feasible for the treatment of adult acute lymphoblastic leukemia? A retrospective analysis of the outcomes of BFM and Hyper-CVAD chemotherapy in two centers","volume":"60","author":"Alacacioglu","year":"2014","journal-title":"Chemotherapy"},{"issue":"6","key":"10.1016\/j.leukres.2022.106885_bib22","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1002\/cam4.1513","article-title":"Survival analysis of adult patients with ALL in Mexico City: first report from the Acute Leukemia Workgroup (ALWG) (GTLA)","volume":"7","author":"Crespo-Solis","year":"2018","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.leukres.2022.106885_bib23","first-page":"459","article-title":"[Acute lymphoblastic leukemia: experience in adult patients treated with hyperCVAD and 0195 Protocol, at the Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n. Cohort 2003-2007]","volume":"60","author":"Arteaga-Ortiz","year":"2008","journal-title":"Rev. Invest Clin."},{"issue":"3","key":"10.1016\/j.leukres.2022.106885_bib24","first-page":"525","article-title":"[Comparison of the Hyper-CVAD with an institutional regimen for the treatment of acute lymphoblastic leukemia in adults in a hospital of Mexico]","volume":"31","author":"Ramos-Pe\u00f1afiel","year":"2014","journal-title":"Rev. Peru. Med Exp. Salud Publica"},{"issue":"1","key":"10.1016\/j.leukres.2022.106885_bib25","first-page":"1","article-title":"High-dose cytarabine-mitoxantrone versus Hyper-CVAD in adult acute lymphoblastic leukemia and burkitt\u2019s lymphoma: a single center experience of two induction regimens","volume":"2","author":"Lu","year":"2009","journal-title":"Open Leuk. J."},{"issue":"3","key":"10.1016\/j.leukres.2022.106885_bib26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000351172","article-title":"Hyper-CVAD regimen in routine management of adult acute lymphoblastic leukemia: a retrospective multicenter study","volume":"130","author":"Buyukasik","year":"2013","journal-title":"Acta Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2022.106885_bib27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3109\/10428194.2010.532889","article-title":"Outcome of treatment of adult acute lymphoblastic leukemia with hyperfractionated cyclophosphamide, doxorubicin, vincristine, dexamethasone\/methotrexate, cytarabine: results from an Australian population","volume":"52","author":"Morris","year":"2011","journal-title":"Leuk. Lymphoma"},{"issue":"6","key":"10.1016\/j.leukres.2022.106885_bib28","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1016\/j.clml.2019.11.003","article-title":"Characteristics and trends of adult acute lymphoblastic leukemia in a large, public safety-net hospital","volume":"20","author":"Gupta","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2022.106885_bib29","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1182\/blood.V126.23.3762.3762","article-title":"Poor outcomes with hyper CVAD induction for t-cell lymphoblastic leukemia\/lymphoma","volume":"126","author":"Kota","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106885_bib30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.clml.2014.03.004","article-title":"Feasibility and Outcome of the Hyper-CVAD Regimen in Patients With Adult Acute Lymphoblastic Leukemia","volume":"15","author":"Portugal","year":"2015","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"issue":"3","key":"10.1016\/j.leukres.2022.106885_bib31","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/cam4.1328","article-title":"Effectiveness of modified hyper-CVAD chemotherapy regimen in the treatment of adult acute lymphoblastic leukemia: a retrospective experience","volume":"7","author":"Jalaeikhoo","year":"2018","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.leukres.2022.106885_bib32","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.leukres.2007.10.019","article-title":"Outcome of treatment with Hyper-CVAD regimen in Chinese patients with acute lymphocytic leukemia","volume":"32","author":"Xu","year":"2008","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2022.106885_bib33","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2013.024","article-title":"Acute lymphoblastic leukemia experience: epidemiology and outcome of two different regimens","volume":"5","author":"Abbasi","year":"2013","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"5","key":"10.1016\/j.leukres.2022.106885_bib34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/ejh.12269","article-title":"High relapse rate of T cell acute lymphoblastic leukemia in adults treated with Hyper-CVAD chemotherapy in Sweden","volume":"92","author":"Kozlowski","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"23","key":"10.1016\/j.leukres.2022.106885_bib35","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1002\/cncr.30231","article-title":"Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis","volume":"122","author":"Sasaki","year":"2016","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.leukres.2022.106885_bib36","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cncr.33529","article-title":"Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.leukres.2022.106885_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/bloodadvances.2016001495","article-title":"US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL","volume":"1","author":"Ravandi","year":"2016","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.leukres.2022.106885_bib38","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.leukres.2022.106885_bib39","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2022.106885_bib40","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2022.106885_bib41","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1200\/JCO.2010.30.1382","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2022.106885_bib42","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.leukres.2022.106885_bib43","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2022.106885_bib44","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2022.106885_bib45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood-2020-138967","article-title":"Expanding use of a modified pediatric intensive regimen for acute lymphoblastic leukemia (ALL) into an older adult population: feasibility and efficacy results","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.leukres.2022.106885_bib46","doi-asserted-by":"crossref","first-page":"7022","DOI":"10.1200\/JCO.2021.39.15_suppl.7022","article-title":"Adult Philadelphia-like B-cell acute lymphoblastic leukemia: characteristics, outcomes, and role of allogeneic hematopoietic cell transplantation in comparison to Philadelphia-positive and Philadelphia-negative acute lymphoblastic leukemia","volume":"39","author":"Rahman","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2022.106885_bib47","doi-asserted-by":"crossref","unstructured":"Aldoss I., Afkhami M., Yang D., Mokhtari S., Tomasian V., Telatar M., et al., editors. Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL). 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; 2021: TCT Meetings.","DOI":"10.1016\/S2666-6367(21)00173-1"},{"issue":"4","key":"10.1016\/j.leukres.2022.106885_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26105","article-title":"Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia","volume":"96","author":"Jonas","year":"2021","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2022.106885_bib49","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.leukres.2022.106885_bib50","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001114?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622001114?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:02:37Z","timestamp":1758934957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":50,"alternative-id":["S0145212622001114"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106885","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106885","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106885"}}